抗肥胖藥物市場：依作用機制、處方藥/非處方藥及地區分類。

據估計，2026年抗肥胖藥物市值為305.8億美元，預計2033年將達到986.3億美元。預計從2026年到2033年，該市場將以18.2%的複合年成長率成長。

肥胖通常是指體內脂肪過多的狀態。成人肥胖的常見標準是身體質量指數（BMI）達到或超過30。抗肥胖藥物是用於降低體內膽固醇水平以減輕體重的藥物。這些藥物透過調節食慾和熱量攝取來影響基本的身體機能。抗肥胖藥物常用於治療肥胖症。美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）已核准多種抗肥胖藥物用於治療肥胖症。

市場動態

肥胖人口的不斷成長及其相關慢性疾病的增加、人們對超重和肥胖問題的日益關注、對抗肥胖藥物需求的成長、研發力度的活性化以及新冠肺炎疫情，預計將成為預測期內推動全球對抗肥胖藥物市場成長的主要因素。例如，2022年6月，美國FDA批准了司美格魯肽2.4毫克，用於輔助低熱量飲食和增加運動，以控制肥胖和/或超重成年人的慢性體重，這些成年人通常伴隨至少一種與Semaglutide相關的疾病（例如高血壓、高膽固醇核准第二型糖尿病）。

此外，2022年1月，全球醫療保健公司諾華公佈了其在臨床實驗藥物vimagumab的II期臨床試驗結果。該藥物已顯示出治療肥胖症的潛在療效。目前，該藥物正在諾華的研發管線中進行進一步研究。

本次調查的主要特點

• 本研究揭示了各個細分市場的潛在商機，並說明了該市場極具吸引力的投資提案矩陣。
• 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
• 本研究根據以下參數創建了全球抗肥胖藥物市場主要公司的概況：公司亮點、產品系列、主要特徵、財務表現和策略。
• 本報告中的見解將使企業負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 這份全球抗肥胖藥物市場報告的目標受群眾外包括行業內的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過利用分析全球抗肥胖藥物市場中使用的各種策略矩陣，更輕鬆地做出決策。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
• 促進因素
• 抑制因子
• 機會
• 影響分析
• 主要進展
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購情景
• 產業趨勢

第4章 全球抗肥胖藥物市場：依藥物類型分類，2021-2033年

• 處方藥
• 非處方藥

第5章 全球抗肥胖藥物市場：依藥物類別分類，2021-2033年

• GLP-1受體促效劑
• MC4R（黑皮質素4受體）促效劑
• 脂肪酶抑制劑
• 去甲腎上腺素促效劑和血清素促效劑
• 聯合治療
• 鈉-葡萄糖共同輸送體2 (SGLT-2) 抑制劑
• 膽汁酸吸附劑
• Amylin類似物
• 其他（例如，處於後期臨床試驗階段的藥物）

第6章 全球抗肥胖藥物市場：依給藥途徑分類，2021-2033年

• 口服
• 腸外
• 其他（經皮）

第7章 全球抗肥胖藥物市場：依類型分類，2021-2033年

• 品牌
• 非專利的

第8章 全球抗肥胖藥物市場：依性別分類，2021-2033年

• 男性
• 女士

第9章 全球抗肥胖藥物市場：依年齡層別分類，2021-2033年

• 成人
• 老年人
• 兒童

第10章 全球抗肥胖藥物市場：依通路分類，2021-2033年

• 零售藥房
• 網路藥房
• 醫院藥房

第11章 全球抗肥胖藥物市場：按地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第12章 競爭格局

• Novo Nordisk
• GlaxoSmithKline
• AstraZeneca
• Pfizer
• Merck & Co.
• Sanofi
• Amgen
• Eli Lilly and Company
• Johnson & Johnson
• Takeda Pharmaceutical Company
• Abbott Laboratories
• Orexigen Therapeutics
• Zafgen
• Rhythm Pharmaceuticals
• Currax Pharmaceuticals

第13章 分析師建議

• 機會分析
• 分析師意見
• Coherent Opportunity Map

第14章 參考文獻與調查方法

• 參考
• 調查方法
• 關於本公司

Anti-Obesity Drug Market is estimated to be valued at USD 30.58 Bn in 2026 and is expected to reach USD 98.63 Bn by 2033, growing at a compound annual growth rate (CAGR) of 18.2% from 2026 to 2033.

Obesity is commonly defined as having too much body mass. A body mass index (BMI) of 30 or higher is the usual benchmark for obesity in adults. Anti-obesity drugs are medications, which are used to reduce body weight by lowering cholesterol levels in the body. These drugs affect the human body's basic functions by modifying appetite or eating calories. Anti-obesity drugs are commonly used for the treatment of obesity. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved several anti-obesity drugs to treat obesity.

Market Dynamics

Increasing obese population and related chronic diseases, increase in concern of being overweight or obese, increase in demand for anti-obesity drugs, increase in research and development, and the outbreak of COVID-19 are major factors expected to drive the growth of the global anti-obesity drug market during the forecast period. For instance, in June 2022, the U.S. FDA approved Semaglutide 2.4 mg for chronic weight management in adults with obesity and/or overweight with at least one weight-related condition (such as high blood pressure or cholesterol, or T2D) for use in addition to a reduced-calorie diet and increased physical activity.

Moreover, in January 2022, Novartis, a global healthcare company, announced the results of its Phase II trial of an investigational product drug called Bimagrumab. The drug has shown potential for the indication of obesity. The drug is currently being studied in the Novartis pipeline.

Key features of the study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global Anti-Obesity Drug Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study are VIVUS Inc., Pfizer Inc., Novo Nordisk, Bayer AG, F Hoffmann-La Roche, Glaxosmithkline, Arena Pharmaceuticals, Eisai Co. Ltd., Takeda Pharmaceutical Company, and Nalpropion Pharmaceuticals Inc., among others.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global anti-obesity drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Anti-Obesity Drug Market

Market Segmentation

• Drug Type Insights (Revenue, USD Bn, 2021 - 2033)
• Prescription Drugs
• Over-the-Counter (OTC) Drugs
• Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
• GLP-1 Receptor Agonists
  • Semaglutide
  • Liraglutide
  • Tirzepatide
• MC4R (Melanocortin-4 Receptor) Agonists
  • Setmelanotide
• Lipase Inhibitors
  • Orlistat
• Noradrenergic & Serotonergic Drugs
  • Phentermine
  • Diethylpropion
  • Phendimetrazine
• Combination Therapies
  • Phentermine/Topiramate
  • Naltrexone/Bupropion
  • Others
• Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
  • Empagliflozin
  • Canagliflozin
• Bile Acid Sequestrants
  • Colesevelam
• Amylin Analogs
  • Pramlintide
• Others (Late Phase Drugs, etc.)
• Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
• Oral
• Parenteral
• Others (Transdermal)
• Type Insights (Revenue, USD Bn, 2021 - 2033)
• Brand
• Generic
• Gender Insights (Revenue, USD Bn, 2021 - 2033)
• Male
• Female
• Age Group Insights (Revenue, USD Bn, 2021 - 2033)
• Adult
• Geriatric
• Pediatric
• Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• Novo Nordisk
• GlaxoSmithKline
• AstraZeneca
• Pfizer
• Merck & Co.
• Sanofi
• Amgen
• Eli Lilly and Company
• Johnson & Johnson
• Takeda Pharmaceutical Company
• Abbott Laboratories
• Orexigen Therapeutics
• Zafgen
• Rhythm Pharmaceuticals
• Currax Pharmaceuticals

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Anti-Obesity Drug Market, By Drug Type
  • Global Anti-Obesity Drug Market, By Drug Class
  • Global Anti-Obesity Drug Market, By Route of Administration
  • Global Anti-Obesity Drug Market, By Type
  • Global Anti-Obesity Drug Market, By Gender
  • Global Anti-Obesity Drug Market, By Age Group
  • Global Anti-Obesity Drug Market, By Distribution Channel
  • Global Anti-Obesity Drug Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Anti-Obesity Drug Market, By Drug Type, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Prescription Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Over-the-Counter (OTC) Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Anti-Obesity Drug Market, By Drug Class, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• GLP-1 Receptor Agonists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Semaglutide
      • Liraglutide
      • Tirzepatide
• MC4R (Melanocortin-4 Receptor) Agonists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Setmelanotide
• Lipase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Orlistat
• Noradrenergic & Serotonergic Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Phentermine
      • Diethylpropion
      • Phendimetrazine
• Combination Therapies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Phentermine/Topiramate
      • Naltrexone/Bupropion
      • Others
• Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Empagliflozin
      • Canagliflozin
• Bile Acid Sequestrants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Colesevelam
• Amylin Analogs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Pramlintide
• Others (Late Phase Drugs, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Anti-Obesity Drug Market, By Route of Administration, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others (Transdermal)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Anti-Obesity Drug Market, By Type, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Brand
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Generic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global Anti-Obesity Drug Market, By Gender, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Male
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Female
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global Anti-Obesity Drug Market, By Age Group, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Geriatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Pediatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

10. Global Anti-Obesity Drug Market, By Distribution Channel, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

11. Global Anti-Obesity Drug Market, By Region, 2021 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

12. Competitive Landscape

• Novo Nordisk
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Abbott Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Orexigen Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Zafgen
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Rhythm Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Currax Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

13. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

14. References and Research Methodology

• References
• Research Methodology
• About us